Form 4: Applied Therapeutics Officer Sells Shares to Cover Tax Obligations

Leslie D. Funtleyder, Interim CEO and CFO of Applied Therapeutics, sold 14,502 shares of common stock to cover tax withholding obligations related to the vesting of restricted stock units.

Summary

• On March 4, 2025, Leslie D. Funtleyder, Interim CEO and CFO of Applied Therapeutics, sold 14,502 shares of common stock at a price of $0.44 per share.
• The sale was executed to cover tax withholding obligations associated with the vesting and settlement of compensatory Restricted Stock Units.
• Following the transaction, Funtleyder directly owns 390,459 shares of Applied Therapeutics common stock.
• Funtleyder has granted power of attorney to certain individuals at Applied Therapeutics and Skadden, Arps, Slate, Meagher & Flom LLP to handle SEC filings on their behalf.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The document simply reports a routine stock sale to cover tax obligations. There's no indication of positive or negative implications for the company's future performance.

Positives

• The sale was explicitly for tax obligations related to vested stock units, indicating a prior grant of equity compensation.

Industry Context

Form 4 filings are standard disclosures required by the SEC when company insiders (officers, directors, or beneficial owners) trade in their company's stock. These filings provide transparency into insider transactions and are closely watched by investors.

Stakeholder Impact

• The stock sale by an officer could be perceived negatively by some shareholders, although it is a common practice for covering tax obligations.

Key Dates